Literature DB >> 27052999

Surgical Outcomes of Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema and Those with Idiopathic Pulmonary Fibrosis without Emphysema.

Seijiro Sato1, Terumoto Koike, Takehisa Hashimoto, Hiroyuki Ishikawa, Akira Okada, Takehiro Watanabe, Masanori Tsuchida.   

Abstract

OBJECTIVES: Combined pulmonary fibrosis and emphysema (CPFE) is a unique disorder. The aim of this study was to compare the surgical outcomes of lung cancer patients with CPFE and those with idiopathic pulmonary fibrosis (IPF) without emphysema.
METHODS: A total of 1548 patients who underwent surgery for primary lung cancer between January 2001 and December 2012 were retrospectively reviewed.
RESULTS: Of the 1548 patients, 55 (3.6%) had CPFE on computed tomography (CT), and 45 (2.9%) had IPF without emphysema. The overall and disease-free 5-year survival rates for patients with CPFE were not significantly worse than those for patients with IPF without emphysema (24.9% vs. 36.8%, p = 0.814; 39.8% vs. 39.3%, p = 0.653, respectively). Overall, 21 (38.1%) patients with CPFE and nine patients (20.0%) with IPF without emphysema developed postoperative cardiopulmonary complications. Patients with CPFE had significantly more postoperative cardiopulmonary complications involving pulmonary air leakage for >6 days, hypoxemia, and arrhythmia than patients with IPF without emphysema (p = 0.048).
CONCLUSIONS: There was no significant difference in survival after surgical treatment between CPFE patients and IPF patients without emphysema, but CPFE patients had significantly higher morbidity than IPF patients without emphysema.

Entities:  

Mesh:

Year:  2016        PMID: 27052999      PMCID: PMC5045848          DOI: 10.5761/atcs.oa.15-00315

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  26 in total

1.  Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity.

Authors:  V Cottin; H Nunes; P-Y Brillet; P Delaval; G Devouassoux; I Tillie-Leblond; D Israel-Biet; I Court-Fortune; D Valeyre; J-F Cordier
Journal:  Eur Respir J       Date:  2005-10       Impact factor: 16.671

Review 2.  Combined pulmonary fibrosis and emphysema syndrome: a review.

Authors:  Matthew D Jankowich; Sharon I S Rounds
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

3.  The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis.

Authors:  Kazuyoshi Kurashima; Noboru Takayanagi; Noriko Tsuchiya; Tetsu Kanauchi; Miyuki Ueda; Toshiko Hoshi; Yosuke Miyahara; Yutaka Sugita
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  "Density mask". An objective method to quantitate emphysema using computed tomography.

Authors:  N L Müller; C A Staples; R R Miller; R T Abboud
Journal:  Chest       Date:  1988-10       Impact factor: 9.410

6.  Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension.

Authors:  Mayra Mejía; Guillermo Carrillo; Jorge Rojas-Serrano; Andrea Estrada; Teresa Suárez; Delfino Alonso; Emilio Barrientos; Miguel Gaxiola; Carmen Navarro; Moisés Selman
Journal:  Chest       Date:  2009-02-18       Impact factor: 9.410

7.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.

Authors:  V Cottin; J Le Pavec; G Prévot; H Mal; M Humbert; G Simonneau; J-F Cordier
Journal:  Eur Respir J       Date:  2009-07-30       Impact factor: 16.671

8.  Cause of regional ventilation-perfusion mismatching in patients with idiopathic pulmonary fibrosis: a combined CT and scintigraphic study.

Authors:  N H Strickland; J M Hughes; D A Hart; M J Myers; J P Lavender
Journal:  AJR Am J Roentgenol       Date:  1993-10       Impact factor: 3.959

9.  Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis.

Authors:  Hidenori Kawasaki; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Yutaka Nishiwaki
Journal:  J Surg Oncol       Date:  2002-09       Impact factor: 3.454

10.  Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis.

Authors:  Takanori Akagi; Takemasa Matsumoto; Taishi Harada; Makoto Tanaka; Takashige Kuraki; Masaki Fujita; Kentaro Watanabe
Journal:  Respir Med       Date:  2009-02-28       Impact factor: 3.415

View more
  5 in total

Review 1.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Clinical characteristics and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis of 13 studies.

Authors:  Chuan Li; Wenwen Wu; Nan Chen; Huizi Song; Tianjian Lu; Zhenyu Yang; Zihuai Wang; Jian Zhou; Lunxu Liu
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone.

Authors:  Chun-Guo Jiang; Qiang Fu; Chun-Ming Zheng
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

4.  Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis.

Authors:  Faria Nasim; Teng Moua
Journal:  ERJ Open Res       Date:  2020-12-14

5.  Combined Pulmonary Fibrosis Emphysema: Role of Cigarette Smoking and Pulmonary Hypertension in a Rural Cohort.

Authors:  Rahul Sangani; Andrew Ghio; Stacey Culp; Zalak Patel; Sunil Sharma
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.